Pharmaceutical composition containing cilostazol and preparation method thereof

A technology of cilostazol and composition, which is applied in the field of pharmaceutical composition containing cilostazol and its preparation, can solve the problems of low-cost cilostazol preparation bioavailability, etc., and achieve low production cost and excellent preparation process. Simple, easy-to-operate effects

Pending Publication Date: 2021-12-10
SUZHOU SIXTH PHARMA PLANT OF JIANGSU WUZHONG PHARMA GROUP
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Therefore, the technical problem to be solved in the present invention is to overcome the defect that the bioavailability of cilostazol preparations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing cilostazol and preparation method thereof
  • Pharmaceutical composition containing cilostazol and preparation method thereof
  • Pharmaceutical composition containing cilostazol and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0048] Example 1

[0049] The present embodiment provides a cilostazol-containing pharmaceutical composition, cilostazol tablets, each containing cilostazol 50mg, prepared according to the following prescription 1000: 53.3 g of granular composition (a sirocco cilostazol 50g, hydroxypropyl methyl cellulose 1.8g, SDS1.5g composition), 27g of microcrystalline cellulose, 23.7 g of corn starch, carmellose calcium (with added) 5g, carmellose calcium (plus) 5g, magnesium stearate 1g. Preparation successively comprising: the step of preparing a granular composition, mixing steps, a step of soft material, granulating step, drying step, whole step, the total mixing step, tabletting step.

[0050] Wherein the step of preparing a particulate composition as cilostazol, SDS, hypromellose mixing weighed by prescription, a jet mill were pulverized to a particle diameter D (90) is of 40 m, particulate composition obtained. Mixing step of prescriptions for the particular weighing the particle compo...

Example Embodiment

[0051] Example 2

[0052] The present embodiment provides a cilostazol-containing pharmaceutical composition, is substantially the same as Example 1 formulation and its preparation method, except that only the preparation of a granular composition, the cilostazol, SDS, hydroxypropyl a mixture of cellulose co-jet mill pulverized to a particle size D (90) is 20μm, resulting particulate composition.

Example Embodiment

[0053] Example 3

[0054] The present embodiment provides a cilostazol-containing pharmaceutical composition, is substantially the same as Example 1 formulation and its preparation method, except that only the preparation of a granular composition, the cilostazol, SDS, hydroxypropyl a mixture of cellulose co-jet mill pulverized to a particle size D (90) is 10μm, resulting particulate composition.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of pharmacy, and particularly provides a cilostazol-containing pharmaceutical composition and a preparation method thereof. The cilostazol-containing pharmaceutical composition comprises a particle composition, the particle composition comprises cilostazol, an adhesive and a surfactant, the particle size D90 of the particle composition is smaller than or equal to 40 micrometers. The inventor finds that the dissolution rate of a cilostazol-containing pharmaceutical preparation, such as a tablet, can be obviously improved by adopting a particle composition comprising an adhesive and a surfactant and controlling the particle size D90 of the particle composition to be less than or equal to 40 microns. Particularly, when the particle size D90 of the particle composition is controlled to be 10-40 microns, the dissolution rate is further improved, and more particularly, when the particle size D90 is controlled to be 10-20 microns, the dissolution rate is optimal.

Description

technical field [0001] The invention relates to the field of pharmacy, in particular to a pharmaceutical composition containing cilostazol and a preparation method thereof. Background technique [0002] Cilostazol, also known as 6-[4-(1-cyclohexyl-1H-pentazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolone, is a Phosphodiesterase inhibitors can inhibit the activity of platelet and vascular smooth muscle phosphodiesterase, increase the concentration of cAMP, and have the effect of anti-platelet aggregation and vasodilation; in addition, it can inhibit the platelet aggregation caused by TXA2, but it does not affect the activity of platelets. Arachidonic acid metabolism increases limb blood flow, improves peripheral blood flow dynamics, and inhibits thrombus formation. Therefore, cilostazol is widely used to improve or treat diseases such as atherosclerosis, Takayasu arteritis, and thrombovascular vasculitis. [0003] The cilostazol preparations currently on the market mainly includ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/20A61K9/16A61K31/4709A61K47/38A61K47/36A61K47/26A61K47/32A61P7/02A61P9/10A61P9/14
CPCA61K9/2059A61K9/2054A61K9/2018A61K9/1652A61K9/1635A61K31/4709A61P7/02A61P9/10A61P9/14
Inventor 李瑜王丹梅王淑啸邓银来卢俞愉胡开方
Owner SUZHOU SIXTH PHARMA PLANT OF JIANGSU WUZHONG PHARMA GROUP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap